natgillin/translations-raw huggingface dataset:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nplate have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Nplate upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Therefore, in patients with intact spleens, the possibility of removing the spleen should be evaluated periodically. 
Zato je treba pri bolnikih z nepoškodovano vranico občasno oceniti možnost za njeno odstranitev.
Long-term studies involving over 1,000 patients, some treated for longer than 5 years, confirmed that Nplate remained effective both in patients whose spleen had been removed and those who had their spleen. 
Dolgoročne študije, v katere je bilo vključenih čez 1 000 bolnikov, od katerih so se nekateri zdravili več kot pet let, so potrdile, da je zdravilo Nplate ostalo učinkovito pri bolnikih, pri katerih je bila vranica odstranjena, in pri tistih, ki so vranico še vedno imeli.
A platelet count below 30 million per millilitre puts patients at risk of bleeding while the normal count is 150 to 400 million per millilitre. 
Pri številu trombocitov, ki je manjše od 30 milijonov na mililiter, so bolniki izpostavljeni tveganju za pojav krvavitve, normalno število trombocitov pa se giblje od 150 do 400 milijonov na mililiter.
For more information about treatment with Nplate, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Nplate preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The first study involved 63 patients whose disease was not controlled despite removal of their spleen. 
V prvo študijo je bilo vključenih 63 bolnikov, pri katerih bolezen kljub odstranitvi vranice ni bila nadzorovana.
The improvement in platelet count was long-lasting and clinically relevant in both groups, although the treatment only manages symptoms and is not a cure. 
Povečanje števila trombocitov je bilo dolgotrajno in klinično pomembno pri obeh skupinah, čeprav to zdravljenje samo lajša simptome in bolezni ne ozdravi.
Because the number of patients with ITP is low, the disease is considered ‘rare', and Nplate was designated an ‘orphan medicine' (a medicine used in rare diseases) on 27 May 2005. 
Ker je bolnikov z imunsko trombocitopenično purpuro malo, velja ta bolezen za redko, zato je bilo zdravilo Nplate 27. maja 2005 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Nplate must not be used in people who are hypersensitive (allergic) to romiplostim, any of the other ingredients, or proteins produced by Escherichia coli (a bacterium). 
Zdravila Nplate ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) romiplostim, katero koli drugo sestavino zdravila ali beljakovine, ki jih tvori bakterija Escherichia coli.
The most common side effects in children include infections of the nose and throat, runny nose, cough, fever, mouth and throat pain, abdominal (belly) pain, diarrhoea, rash and bruising. 
Najpogostejši neželeni učinki pri otrocih so okužbe nosu in žrela, izcedek iz nosu, kašelj, vročina, bolečina v ustih in žrelu, abdominalna (trebušna) bolečina, driska, izpuščaj in podplutbe.
The full EPAR for Nplate can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nplate je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The company that markets Nplate will provide doctors a ‘dosing calculator' to help them calculate the sometimes very small volumes of Nplate that need to be injected. 
Družba, ki trži zdravilo Nplate, bo zdravnikom priskrbela računalo za odmerjanje, ki jim bo pomagalo izračunati prostornino zdravila Nplate, ki jo je treba injicirati in ki je včasih zelo majhna.
All studies compared Nplate with placebo (a dummy treatment). 
V vseh študijah so zdravilo Nplate primerjali s placebom (zdravilom brez učinkovine).
The starting dose depends on the patient's weight, and is then adjusted to maintain platelet counts at the target levels. 
Začetni odmerek je odvisen od telesne mase bolnika, nato pa ga je treba za ohranjanje števila trombocitov na ciljni ravni prilagoditi.
Nplate is a powder that is made up into a solution for injection. 
Zdravilo Nplate je prašek za pripravo raztopine za injiciranje.
The most common side effects with Nplate in adults (seen in more than 1 patient in 10) include headache, infections of the nose and throat and allergic (hypersensitivity) reactions such as rash, itching and rapid swelling under the skin. 
Najpogostejši neželeni učinki zdravila Nplate pri odraslih (opaženi pri več kot 1 bolniku od 10) so glavobol, okužbe nosu in žrela ter alergijske (preobčutljivostne) reakcije, npr. izpuščaj, srbenje in hitro podkožno otekanje.
The spleen, an organ behind the stomach, is involved in the removal of platelets from the blood. 
Vranica, organ za želodcem, sodeluje pri odstranjevanju trombocitov iz krvi.
For practical information about using Nplate, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Nplate naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Two main studies in adults and a third one in children found Nplate effective for the treatment of longstanding ITP. 
Dve glavni študiji pri odraslih in tretja pri otrocih so pokazale, da je zdravilo Nplate učinkovito pri zdravljenju kronične imunske trombocitopenične purpure.
Nplate contains the active substance romiplostim. 
Zdravilo Nplate vsebuje učinkovino romiplostim.
Nplate is used in patients from 1 year of age with long-term immune thrombocytopenic purpura (ITP), a disease in which the patient's immune system destroys platelets (components in the blood that help it to clot). 
Zdravilo Nplate se uporablja pri bolnikih, starejših od enega leta, s kronično imunsko trombocitopenično purpuro (ITP), tj. boleznijo, pri kateri bolnikov imunski sistem uničuje trombocite (sestavino krvi, ki sodeluje pri njenem strjevanju).
By mimicking the action of thrombopoietin, romiplostim stimulates the production of platelets, thereby increasing blood platelet counts and reducing the risk of bleeding. 
S posnemanjem delovanja trombopoetina ta spodbuja nastajanje trombocitov ter tako poveča njihovo število v krvi in zmanjša tveganje za krvavitev.
For the full list of side effects reported with Nplate, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Nplate, glejte navodilo za uporabo.
Nplate can be used in patients whose spleen has been removed to control the disease and in those who still have a spleen. 
Uporablja se lahko pri bolnikih z odstranjeno vranico, da bi se bolezen nadzorovala, in pri tistih, ki jo še imajo.
The Agency noted that Nplate was effective in patients who had had their spleen removed, as well as in patients who had not had their spleen removed. 
Menila je, da je bilo zdravilo Nplate učinkovito pri bolnikih, ki so jim vranico odstranili, pa tudi pri bolnikih, ki jim vranice niso odstranili.
Treatment should be stopped if the platelet count does not rise enough to reduce the risk of bleeding after 4 weeks of treatment with the maximum dose of Nplate. 
Zdravljenje z zdravilom Nplate je treba po štirih tednih zdravljenja z največjim odmerkom prekiniti, če se število trombocitov ne poveča dovolj, da bi se zmanjšalo tveganje za krvavitev.
In the body, a hormone called ‘thrombopoietin' normally stimulates the production of platelets in the bone marrow. 
V telesu nastajanje trombocitov v kostnem mozgu običajno spodbuja hormon, imenovan „trombopoetin“.
The study in children involved 62 patients aged 1 to less than 18 years whose ITP had been treated previously (including some whose spleen had been removed). 
V študijo pri otrocih je bilo vključenih 62 bolnikov, starih od enega leta do manj kot 18 let, pri katerih je bila imunska trombocitopenična purpura že zdravljena (vključno z nekaterimi bolniki, pri katerih je bila odstranjena vranica).
How does Nplate work? 
Kako zdravilo Nplate deluje?
How is Nplate used? 
Kako se zdravilo Nplate uporablja?
The active substance in Nplate, romiplostim, stimulates the production of platelets. 
Učinkovina v zdravilu Nplate, romiplostim, spodbuja nastajanje trombocitov.
Platelet count rose above the threshold in 38% of patients who received Nplate (16 out of 42) compared with none of the 21 patients receiving placebo. 
Število trombocitov se je zvišalo nad prag pri 38 % bolnikov, ki so prejemali zdravilo Nplate (16 od 42), v primerjavi z nobenim od 21 bolnikov, ki so prejemali placebo.
Patients with ITP have low platelet counts and are at risk of bleeding. 
Bolniki z imunsko trombocitopenično purpuro imajo nizko število trombocitov in povečano tveganje za krvavitve.
The second study involved 62 patients whose ITP had been treated previously (but who did not have their spleen removed). 
V drugo študijo je bilo vključenih 62 bolnikov, pri katerih so imunsko trombocitopenično purpuro predhodno zdravili (niso pa jim odstranili vranice).
Platelet count rose above the threshold in 61% of patients who received Nplate (25 out of 41) compared with 5% receiving placebo (1 out of 21). 
Število trombocitov se je zvišalo nad prag pri 61 % (25 od 41) bolnikov, ki so prejemali zdravilo Nplate, v primerjavi s 5 % (1 od 21) bolnikov, ki so prejemali placebo.
Platelet count rose above the threshold in 52% of patients who received Nplate (22 out of 42) compared with 10% receiving placebo (2 out of 
Število trombocitov se je zvišalo nad prag pri 52 % (22 od 42) bolnikov, ki so prejemali zdravilo Nplate, v primerjavi z 10 % (2 od 20) bolnikov, ki so prejemali placebo.
What measures are being taken to ensure the safe and effective use of Tegsedi? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Tegsedi?
The European Medicines Agency therefore decided that Tegsedi's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Tegsedi večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Why is Tegsedi authorised in the EU? 
Zakaj je bilo zdravilo Tegsedi odobreno v EU?
The medicine is available as a solution for injection under the skin in pre-filled syringes (284 mg). 
Zdravilo je na voljo kot raztopina za injiciranje pod kožo v napolnjenih injekcijskih brizgah (284 mg).
The first injection should be given under the supervision of a qualified healthcare professional, and patients or carers can give the subsequent injections after receiving appropriate training. 
Prvo injekcijo je treba dati pod nadzorom usposobljenega zdravstvenega delavca, bolniki ali njihovi skrbniki pa lahko po opravljenem ustreznem usposabljanju injekcije dajejo sami.
What is Tegsedi and what is it used for? 
Kaj je zdravilo Tegsedi in za kaj se uporablja?
Further information on Tegsedi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Tegsedi so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The recommended dose is one injection once a week, given under the skin in the belly, upper thigh or upper arm. 
Priporočeni odmerek je ena injekcija enkrat tedensko, ki se daje pod kožo v trebuh, zgornji del stegen ali nadlaket.
This reduces production of transthyretin, thereby reducing the formation of amyloids and relieving the symptoms of hATTR amyloidosis. 
Tako se zmanjša tvorba transtiretina, kar zmanjša nastajanje amiloidov in olajša simptome amiloidoze hATTR.
In light of the unmet medical need, the safety profile of Tegsedi was considered acceptable and the risks to be manageable with specific monitoring, dose reduction and stopping rules. 
Ob upoštevanju neizpolnjene medicinske potrebe je bil varnostni profil zdravila Tegsedi ocenjen kot sprejemljiv, tveganja pa obvladljiva ob upoštevanju posebnih pravil za spremljanje, zmanjšanje odmerka in ukinitev zdravila.
Tegsedi is used in adult patients in the first two stages of the nerve damage (stage 1, when the patient is able to walk unaided, and stage 2, when the patient can still walk but needs help). 
Zdravilo Tegsedi se uporablja pri odraslih bolnikih v prvih dveh stadijih poškodbe živcev (v 1. stadiju, v katerem bolnik lahko hodi brez pomoči, in 2. stadiju, v katerem bolnik še lahko hodi, vendar potrebuje pomoč).
The broken protein forms amyloid deposits in tissues and organs around the body, including around nerves, where it interferes with their normal functions. 
Razgrajena beljakovina tvori amiloidne skupke v tkivih in organih po vsem telesu, tudi okoli živcev, kjer moti njihovo normalno delovanje.
The main measures of effectiveness were the changes in the patients' nerve damage and quality of life, as measured using standard scales called ‘mNIS+7' and ‘Norfolk QoL-DN' respectively. 
Glavno merilo učinkovitosti so bile spremembe poškodbe živcev in kakovosti življenja bolnikov, izmerjene s standardnima lestvicama „mNIS+7“ oziroma „Norfolk QoLDN“.
As for all medicines, data on the use of Tegsedi are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Tegsedi stalno spremljajo.
What benefits of Tegsedi have been shown in studies? 
Kakšne koristi zdravila Tegsedi so se pokazale v študijah?
An overview of Tegsedi and why it is authorised in the EU 
Pregled zdravila Tegsedi in zakaj je odobreno v EU
Tegsedi must not be used by patients with low platelet counts (less than 100x109/l), and by patients with severe kidney or liver problems. 
Zdravilo Tegsedi se ne sme uporabljati pri bolnikih z zmanjšanim številom trombocitov (pod 100 x 109/l) in pri bolnikih z resnimi težavami z ledvicami ali jetri.
Side effects reported with Tegsedi are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Tegsedi, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
The most common side effects with Tegsedi (which may affect more than 1 in 10 people) are reactions at the site of injection, nausea (feeling sick), low level of red blood cells, headache, fever, peripheral oedema (swelling, especially of the ankles and feet), chills, vomiting and low blood platelet counts which can lead to bleeding and bruising. 
Najpogostejši neželeni učinki zdravila Tegsedi (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so reakcije na mestu injiciranja, navzea (siljenje na bruhanje), nizka vrednost rdečih krvnih celic, glavobol, povišana telesna temperatura, periferni edem (otekanje, zlasti gležnjev in stopal), mrzlica, bruhanje in zmanjšano število trombocitov v krvi, kar lahko privede do krvavitve in podplutb.
hATTR is rare, and Tegsedi was designated an ‘orphan medicine' (a medicine used in rare diseases) on 26 March 2014. 
Bolezen hATTR je redka, zato je bilo zdravilo Tegsedi 26. marca 2014 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tegsedi have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Tegsedi upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The active substance in Tegsedi, inotersen, is an ‘antisense oligonucleotide', a very short piece of synthetic genetic material that has been designed to attach to and block the genetic material of the cell responsible for producing transthyretin. 
Učinkovina zdravila Tegsedi, inotersen, je „protismerni oligonukleotid“, tj. zelo kratek košček umetnega genetskega materiala, ki je bil zasnovan tako, da se pritrdi na genetski material celice, odgovorne za tvorbo transtiretina, in ga zavira.
For more information about using Tegsedi, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Tegsedi glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The company that markets Tegsedi will provide an alert card for patients with information about the safety of the medicine and how to manage side effects. 
Podjetje, ki trži zdravilo Tegsedi, bo priskrbelo opozorilno kartico za bolnike, kjer bodo navedene informacije o varnosti zdravila in obvladovanju neželenih učinkov.
After 15 months of treatment, the mNIS+7 score, used for assessing nerve damage, worsened by a lesser extent with Tegsedi (around 11 points) than with placebo (around 25 points). 
Po 15 mesecih zdravljenja se je rezultat po lestvici mNIS+7, ki se uporablja za ocenjevanje poškodb živcev, pri zdravilu Tegsedi poslabšal v manjšem obsegu (za približno 11 točk) kot pri placebu (za približno 25 točk).
In patients with hATTR, a protein called transthyretin which circulates in the blood is defective and breaks easily. 
Pri bolnikih s hATTR je beljakovina transtiretin v krvnem obtoku okvarjena in se hitro razgradi.
Tegsedi can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of patients with hATTR. 
Predpisovanje in izdaja zdravila Tegsedi je le na recept, zdravljenje pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s hATTR.
How is Tegsedi used? 
Kako se zdravilo Tegsedi uporablja?
Tegsedi is a medicine used to treat nerve damage caused by hereditary transthyretin amyloidosis (hATTR), a disease in which proteins called amyloids build up in tissues around the body including around the nerves. 
Zdravilo Tegsedi se uporablja za zdravljenje poškodbe živcev, ki jo povzroča transtiretinska amiloidoza (hATTR), tj. bolezen, pri kateri se beljakovine, imenovane amiloidi, kopičijo v tkivih po telesu, tudi okoli živcev.
Tegsedi was shown to be effective in the treatment of stage 1 or stage 2 nerve damage in patients with hATTR; available data were not sufficient to assume a beneficial effect in stage 3 patients (those confined to a wheelchair). 
Zdravilo Tegsedi se je izkazalo za učinkovito pri zdravljenju 1. ali 2. stadija poškodbe živcev pri bolnikih s hATTR; razpoložljivi podatki ne zadoščajo za izpeljavo predpostavke o koristih pri bolnikih v 3. stadiju (ki so na invalidskem vozičku).
What are the risks associated with Tegsedi? 
Kakšna tveganja so povezana z zdravilom Tegsedi?
As Tegsedi can cause a reduction in the number of platelets in the blood (posing a risk of bleeding), blood platelet counts need to be monitored during treatment with Tegsedi, and the dose of the medicine and how often it is given adjusted accordingly. 
Ker zdravilo Tegsedi lahko povzroči zmanjšanje števila trombocitov v krvi (kar pomeni tveganje za krvavitev), je treba med zdravljenjem z zdravilom Tegsedi spremljati število trombocitov v krvi ter skladno s tem prilagoditi odmerek in pogostnost dajanja zdravila.
Quality of life, measured by the Norfolk QoL-DN score, worsened by around 4 points in patients treated with Tegsedi, compared with around 13 points in those on placebo. 
Kakovost življenja, merjena z lestvico Norfolk QoL-DN, se je pri bolnikih, zdravljenih z zdravilom Tegsedi, poslabšala za približno 4 točke, pri bolnikih, ki so prejemali placebo, pa za približno 13 točk.
In one main study involving 173 hATTR patients with stage 1 or 2 nerve damage, Tegsedi was shown to be more effective than placebo (a dummy treatment) at slowing down the nerve damage caused by the disease. 
V eni glavni študiji, ki je vključevala 173 bolnikov s hATTR v 1. ali 2. stadiju poškodbe živcev, so dokazali, da je zdravilo Tegsedi pri upočasnitvi poškodbe živcev, ki jo povzroča bolezen, učinkovitejše od placeba (zdravila brez učinkovine).
How does Tegsedi work? 
Kako zdravilo Tegsedi deluje?
For the full list of side effects of Tegsedi, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tegsedi, glejte navodilo za uporabo.
Other information about Tegsedi 
Druge informacije o zdravilu Tegsedi
Rare: Hepatitis. 
Redki: hepatitis.
However it is not clear whether these cases were due to the antiretroviral treatment or to the underlying HIV disease. 
Vendar ni pojasnjeno, ali so bili ti primeri posledica protiretrovirusnega zdravljenja ali osnovne bolezni HIV.
Teva Finland Oy Finnland 
Teva Finland Oy
Pancreatitis: Cases of pancreatitis have occurred rarely. 
Pankreatitis: primeri pankreatitisa so bili redki.
Date of latest renewal: 11 September 2014 
Datum prve odobritve: 10. december 2009 Datum zadnjega podaljšanja: 11. september 2014
Absorption differences have been observed between adult and paediatric populations (see “Special populations”). 
Pri odraslih in pediatrični populaciji je bila opažena razlika v absorpciji (glejte »Posebne populacije«).
In vitro susceptibility testing has not been standardised and results may vary according to methodological factors. 
Testiranje občutljivosti in vitro ni standardizirano in rezultati se lahko spreminjajo glede na metodološke dejavnike.
Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000). 
Kategorije pogostosti so opredeljene tako: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000) in zelo redki (< 1/10.000).
mannitol, lactitol or maltitol), if taken regularly. 
manitol, laktitol, maltitol), če se jemljejo redno,
• serious allergic reaction causing swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing 
• resna alergijska reakcija, ki povzroči otekanje obraza, jezika in grla, kar lahko povzroči težave pri požiranju ali dihanju,
This is not considered to be of significance to patient safety and therefore no dosage adjustments are necessary. 
Menijo, da to ne ogroža varnosti bolnikov, zato prilagajanje odmerkov ni potrebno.
From intravenous studies, the mean volume of distribution is 1.3 l/kg. 
V študijah z intravenskimi odmerki so ugotovili, da je povprečni volumen porazdelitve 1,3 l/kg.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines or other medicines you bought without a prescription. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno z zdravili rastlinskega izvora ali drugimi zdravili, ki ste jih kupili brez recepta.
No studies on the effects on the ability to drive and use machines have been performed. 
Študij o vplivu na sposobnost vožnje in uporabe strojev niso opravili.
Rare: Pancreatitis, elevations in serum amylase. 
Redki: pankreatitis, povišanje vrednosti amilaz v serumu.
Manufacturer 
Proizvajalci
CD4 cells are a type of white blood cells, that are important in helping your body to fight infection. 
Celice CD4 so vrsta belih krvnih celic, ki opravljajo pomembno vlogo v boju z okužbo.
Pharmacotherapeutic group: nucleoside analogue, ATC Code: J05AF05. 
Farmakoterapevtska skupina: nukleozidni analog; oznaka ATC: J05AF05.
Children less than three months of age: The limited data available are insufficient to propose specific dosage recommendations (see section 5.2). 
Otroci, mlajši od treh mesecev: Na voljo ni dovolj podatkov, da bi bilo mogoče priporočiti specifične odmerke (glejte poglavje 5.2).
These symptoms are probably caused by the body's immune system becoming stronger, so that the body starts to fight these infections. 
Ti simptomi so verjetno posledica okrepitve imunskega sistema, s tem, da se organizem zopet prične boriti proti tem okužbam.